1. Table of Contents
1.1 List of Tables
1.2 List of Figures

2. Global Interstitial Cystitis Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Interstitial Cystitis Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Interstitial Cystitis pipeline, H1- 2019
3.5 Mechanism of Action wise Interstitial Cystitis Pipeline Candidates

4 Alivio Therapeutics Inc  Interstitial Cystitis Pipeline Details
4.1 Alivio Therapeutics Inc  Business Profile
4.2 Alivio Therapeutics Inc  Interstitial Cystitis Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Astellas Pharma Inc Interstitial Cystitis Pipeline Details
5.1 Astellas Pharma Inc Business Profile
5.2 Astellas Pharma Inc Interstitial Cystitis Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 GlycoMira Therapeutics Inc Interstitial Cystitis Pipeline Details
6.1 GlycoMira Therapeutics Inc Business Profile
6.2 GlycoMira Therapeutics Inc Interstitial Cystitis Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Idera Pharmaceuticals Inc Interstitial Cystitis Pipeline Details
7.1 Idera Pharmaceuticals Inc Business Profile
7.2 Idera Pharmaceuticals Inc Interstitial Cystitis Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Kyorin Pharmaceutical Co Ltd Interstitial Cystitis Pipeline Details
8.1 Kyorin Pharmaceutical Co Ltd Business Profile
8.2 Kyorin Pharmaceutical Co Ltd Interstitial Cystitis Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Lipella Pharmaceuticals Inc Interstitial Cystitis Pipeline Details
9.1 Lipella Pharmaceuticals Inc Business Profile
9.2 Lipella Pharmaceuticals Inc Interstitial Cystitis Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Mirae Cell Bio Co Ltd Interstitial Cystitis Pipeline Details
10.1 Mirae Cell Bio Co Ltd Business Profile
10.2 Mirae Cell Bio Co Ltd Interstitial Cystitis Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Pierre Fabre Pharmaceuticals Inc Interstitial Cystitis Pipeline Details
11.1 Pierre Fabre Pharmaceuticals Inc Business Profile
11.2 Pierre Fabre Pharmaceuticals Inc Interstitial Cystitis Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 UCB SA Interstitial Cystitis Pipeline Details
12.1 UCB SA Business Profile
12.2 UCB SA Interstitial Cystitis Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Urigen Pharmaceuticals Inc Interstitial Cystitis Pipeline Details
13.1 Urigen Pharmaceuticals Inc Business Profile
13.2 Urigen Pharmaceuticals Inc Interstitial Cystitis Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 Xigen SA Interstitial Cystitis Pipeline Details
14.1 Xigen SA Business Profile
14.2 Xigen SA Interstitial Cystitis Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. Latest Interstitial Cystitis Drug Pipeline Developments, 2019

16. Appendix
16.1 About Us
16.2 Sources and Methodology
16.3 Contact Information

Companies Mentioned:
Alivio Therapeutics Inc 
Astellas Pharma Inc
GlycoMira Therapeutics Inc
Idera Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Pierre Fabre Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA